MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Adagrasib
CAS No. : 2326521-71-3
MCE 国际站：Adagrasib
产品活性：Adagrasib (MRTX849) 是一种有效，口服可用，突变选择性的 KRAS G12C 共价抑制剂，具有潜在抗肿瘤活性的。Adagrasib 在半胱氨酸 12 残基处与 KRAS G12C 共价结合，将蛋白锁定在非活性的 GDP 结合构象中，并抑制 KRAS 依赖性信号转导。
研究领域：GPCR/G Protein | MAPK/ERK Pathway
作用靶点：Ras
In Vitro: Adagrasib (MRTX849) (0.1-10000 nM; 3-day/2D conditions; 12-day/3D conditions) potently inhibits cell growth in the vast majority of KRAS G12C-mutant cell lines with IC50s ranging between 10 and 973 nM in the 2D format and between 0.2 and 1042 nM in the 3D format.
Adagrasib (0.24-1000 nM; 24 hours) inhibits KRAS-dependent signaling targets including ERK1/2 phosphorylation (Thr202/Tyr204 ERK1; pERK), S6 phosphorylation (RSK-dependent Ser235/236; pS6) and expression of the ERK-regulated DUSP6.
In Vivo: Adagrasib (1-100 mg/kg; i.g.; daily until day 16) demonstrates dose-dependent anti-tumor efficacy over a well-tolerated dose range, and the maximally efficacious dose of MRTX849 is between 30-100 mg/kg/day.
相关产品：Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Oxygen Sensing Compound Library | Ferroptosis Compound Library | Orally Active Compound Library | Chemical Probe Library | Glutamine Metabolism Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | FDA-Approved Anticancer Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Anti-Hematopathy Compound Library | Bioactive Compound Library Max | Sotorasib | MRTX1133 | BI-2865 | BI-3406 | Ketoconazole | BI-2852 | RMC-6236 | NSC 23766 trihydrochloride | RMC-7977 | Rhosin hydrochloride | ML141 | Divarasib | N-Acetylneuraminic acid | Lonafarnib | CID-1067700 | EHT 1864 | RMC-6291 | MBQ-167 | BAY-293 | MRTX0902 | RMC-9805 | LC-2 | CASIN | Opnurasib | Salirasib | Levistolide A | ML-098 | CCG-1423 | EHop-016 | ARS-1620
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
